C4B and cancer: These findings were further corroborated by Bolton et al. and Stonestrom et al., who each examined an expanded MSK-IMPACT cohort of 24,146 and 42,714 patients with cancer (including 8,810 patients studied by Coombs, et al.; ref. 4), confirming that approximately 30% of them carried CH (5, 13).